A study to determine replacement of anti-PD-1 drugs during treatment on safety and anti-PD-1 response in patients with melanoma and lung cancer
Latest Information Update: 09 Jul 2023
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Prolgolimab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
Most Recent Events
- 09 Jul 2023 New trial record
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology